Karyopharm Therapeutics Inc.

KPTI

$108M

Micro Cap

NASDAQPharmaceutical Preparations🇺🇸North AmericaNEWTON279 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

7 upcoming, 1 past

⭐Phase 3Next

Ruxolitinib Phase 3 Results Expected

March 2026~Ruxolitinib353

Primary completion for Ruxolitinib trial (NCT04562389) in Myelofibrosis

Source

⭐Phase 3

Selinexor Phase 3 Results Expected

March 2026~Selinexor353

Primary completion for Selinexor trial (NCT04562389) in Myelofibrosis

Source

Phase 2

Ruxolitinib Phase 2 Results Expected

April 2026~Ruxolitinib118

Primary completion for Ruxolitinib trial (NCT05980806) in Myelofibrosis

Source

Phase 2

Selinexor 40 mg Phase 2 Results Expected

April 2026~Selinexor 100 mg118

Primary completion for Selinexor 40 mg trial (NCT05980806) in Myelofibrosis

Source

Phase 2

Selinexor 60 mg Phase 2 Results Expected

April 2026~Selinexor 60 mg118

Primary completion for Selinexor 60 mg trial (NCT05980806) in Myelofibrosis

Source

⭐Phase 3

Selinexor Phase 3 Results Expected

August 2026~Selinexor276

Primary completion for Selinexor trial (NCT05611931) in Endometrial Cancer

Source

Phase 2

Selinexor Phase 2 Results Expected

September 2026~Selinexor112

Primary completion for Selinexor trial (NCT04562870) in Myelofibrosis

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Ruxolitinib

Phase 3

Myelofibrosis

Selinexor (combination therapy)

Phase 3

Relapsed/Refractory Diffuse Large B-cell Lymphoma

Bortezomib

Phase 3

Multiple Myeloma

Dexamethasone

Phase 3

Multiple Myeloma

Selinexor

Phase 3

Multiple Myeloma, Refractory

KPT-8602

Phase 2

Relapsed/Refractory Multiple Myeloma (RRMM)

Selinexor 60 mg

Phase 2

Myelofibrosis

Hydroxyurea

Phase 2

Acute Myeloid Leukemia (AML)

Selinexor 100 mg

Phase 2

Non-Small Cell Lung Carcinoma (NSCLC)

Lenalidomide

Phase 2

Multiple Myeloma

Drug Name	Phase	Indication	Designations
Ruxolitinib	Phase 3	Myelofibrosis	-
Selinexor (combination therapy)	Phase 3	Relapsed/Refractory Diffuse Large B-cell Lymphoma	-
Bortezomib	Phase 3	Multiple Myeloma	-
Dexamethasone	Phase 3	Multiple Myeloma	-
Selinexor	Phase 3	Multiple Myeloma, Refractory	-
KPT-8602	Phase 2	Relapsed/Refractory Multiple Myeloma (RRMM)	-
Selinexor 60 mg	Phase 2	Myelofibrosis	-
Hydroxyurea	Phase 2	Acute Myeloid Leukemia (AML)	-
Selinexor 100 mg	Phase 2	Non-Small Cell Lung Carcinoma (NSCLC)	-
Lenalidomide	Phase 2	Multiple Myeloma	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

KPTI News